AEterna Zentaris Inc is a pharmaceutical company specializing in biotechnology application to manufacture drugs and diagnostic products.
The specialty biotech firm is domiciled in South Carolina, the United States. Its common stocks trade on TSX and NASDAW under the ticker symbol ‘AEZS’.
The biopharmaceutical company develops and commercializes pharmaceutical and diagnostic tests for numerous hormone deficiencies, disorders, and diseases. The commercialized and development product pipeline includes:
It is used in the treatment of Adult Growth Hormone Deficiency. Macimorelin oral test is approved by the U.S. FDA and European Commission for adult growth hormone disorders, the firm claims. It claims to presently working with Novo Nordisk to conduct clinical tests to develop Macimorelin for Childhood-onset Growth Hormone Deficiency (CGHD).
On May 13, 2021, AEterna initiated its Pivotal Phase-3 Detect Trial (AEZS-130-P02) to ensure the safety and effects of the Macimorelin diagnosis test for CGHD.
The biotech firm’s therapeutic and vaccine development pipeline consists of the following:
It is a therapeutic treatment for Neuromyelitis Optica Spectrum Disorder. In January 2021, the biotech company entered into an agreement with Germany-based Julius-Maximilians-University Wuerzburg for exclusive patent right to market and sell AIM Biologicals for treatment. In addition, the company reportedly works with acclaimed professionals to develop diagnosis solutions for NMOAD, inflammatory CNS disorders and autoimmune diseases of the nervous system.
The company aims to provide treatment solutions for Lou Gehrig's disease and Amyotrophic Lateral Sclerosis under this product pipeline.
AEterna reportedly commenced the pre-clinical program for qualifying the product as treatment for ALS at the University of Queensland.
The company, through its subsidiary Aeterna Zentaris GmbH collaborated with the UK-based University of Sheffield and started the first human clinical trial for the product on May 6, 2021, reportedly. It is being developed for patients suffering from primary hypoparathyroidism.
Amid the COVID-19 pandemic, Aeterna Zentaris GmbH entered into an agreement with Julius-Maximilians-University Wuerzburg to develop oral coronavirus vaccine, which is presently under pre-clinical stage.
In partnership with the company, MegaPharm Ltd is expected to receive necessary approvals for marketing of Macimorelin in Palestinian Authority and Israel.